-
Most Popular
Search Results
240 results for orex
10 Biotechnology Stocks to Sell Now
The overall ratings of 10 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong…
10 Hottest Small-Cap Stocks of 2012
These 10 small to midsize businesses have seen returns ranging from 210 to 670% in just nine months. See which sector makes up most of…
10 Biotechnology Stocks to Sell Now
This week, the overall grades of 10 biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or…
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here’s why VVUS stock is a must
13 Pharmaceuticals Stocks to Sell Now
The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F”…
Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)
The AMA has ruled to classify obesity more intensely — as a “disease.” But are ARNA and VVUS investors justified in being excited?
16 Pharmaceuticals Stocks to Sell Now
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong…
16 Biotechnology Stocks to Sell Now
This week, the overall grades of 16 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or…
Sears, Angie’s List Spike — Thursday’s IP Market Recap
Sears Holdings and Angie’s List both posted quarterly losses Thursday, but other positive news sent their shares higher.
Investors Bid Up Homebuilders, Energy Stocks — Monday’s IP Market Recap
A rise in pending home sales lifts equities to a flat day overall. Lowe’s joins the homebuilders’ rise for the day.
FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets
Vivus and Orexigen’s diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.
The Sad Skinny On Obesity-Drug Stocks
Obesity drugs have yet to produce a big payday.
Bet on a Bounce with These Biotech ETFs
Biotech stocks may have taken a beating lately, but that may just make these biotech ETFs more of a bargain.
5 Ebola Stocks – Invest in Preventing a U.S. Ebola Outbreak
Ebola stocks are in the news thanks to fears of a U.S. outbreak. So which Ebola stock investments are safe, and which are big risks?
3 Huge Healthcare Trends Can Fatten Your Portfolio
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities
Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution
Arena Pharmaceuticals (ARNA) stock is up 35% this year, but its prospects are crippled by risks as a recent secondary offering raises eyebrows.
Why Now Is the Time to Pile Back Into Biotech Stocks (IBB, XBI)
For years, biotech stocks have outperformed the market. In light of their recent downturn, now’s a fine time to buy biotech ETFs like IBB and…
Vivus, Inc. (VVUS): Earnings Preview
The VIVUS earnings report coming on Monday could be a harsh reality check about the long-term prospects for Qsymia.
Don’t Buy Orexigen on Diet Pill Hopes
Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that’s brought nothing but disappointment to investors: weight-loss drugs.
Hide Out from Volatility in … Biotech?
On April 19, Zafgen sold six million shares, one million more than initially planned.
Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena’s numbers. They might be pleasantly surprised.
2 – 10 of 240 results
